PALAZZUOLI, ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 7.892
EU - Europa 4.205
AS - Asia 2.575
SA - Sud America 533
AF - Africa 55
OC - Oceania 7
Totale 15.267
Nazione #
US - Stati Uniti d'America 7.830
RU - Federazione Russa 1.200
CN - Cina 940
GB - Regno Unito 896
SG - Singapore 803
IE - Irlanda 562
BR - Brasile 455
SE - Svezia 309
IT - Italia 287
UA - Ucraina 276
VN - Vietnam 235
DE - Germania 234
HK - Hong Kong 230
FI - Finlandia 150
KR - Corea 143
FR - Francia 141
IN - India 66
AR - Argentina 39
CA - Canada 26
TR - Turchia 26
MX - Messico 25
BD - Bangladesh 23
BE - Belgio 23
ES - Italia 23
IQ - Iraq 21
CZ - Repubblica Ceca 19
NL - Olanda 18
ZA - Sudafrica 18
JP - Giappone 17
PL - Polonia 16
ID - Indonesia 9
KE - Kenya 9
EC - Ecuador 8
SA - Arabia Saudita 8
CI - Costa d'Avorio 7
CO - Colombia 7
PE - Perù 7
PY - Paraguay 7
AT - Austria 6
DK - Danimarca 6
PK - Pakistan 6
UZ - Uzbekistan 6
AU - Australia 5
CL - Cile 5
GR - Grecia 5
IL - Israele 5
LT - Lituania 5
MA - Marocco 5
NP - Nepal 5
AZ - Azerbaigian 4
BG - Bulgaria 4
EG - Egitto 4
IR - Iran 4
NO - Norvegia 4
VE - Venezuela 4
AL - Albania 3
DZ - Algeria 3
JO - Giordania 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
PA - Panama 3
PS - Palestinian Territory 3
PT - Portogallo 3
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
IM - Isola di Man 2
JM - Giamaica 2
LV - Lettonia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
BF - Burkina Faso 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
CH - Svizzera 1
CR - Costa Rica 1
ET - Etiopia 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
LY - Libia 1
MU - Mauritius 1
NG - Nigeria 1
SI - Slovenia 1
TH - Thailandia 1
TZ - Tanzania 1
Totale 15.267
Città #
Dallas 3.319
Southend 746
Dublin 556
Fairfield 535
Singapore 459
Ashburn 452
Moscow 371
Chandler 311
Woodbridge 278
Ann Arbor 264
Beijing 260
Houston 232
Santa Clara 229
Hong Kong 228
Jacksonville 219
Seattle 216
Wilmington 214
Cambridge 172
Hefei 167
Seoul 141
Dong Ket 117
Princeton 92
Los Angeles 91
Munich 84
New York 83
Nanjing 77
Siena 77
The Dalles 62
Turku 50
Helsinki 49
Shanghai 47
Dearborn 44
São Paulo 44
Boardman 42
Ho Chi Minh City 40
Buffalo 38
San Nicola la Strada 37
London 30
Hanoi 28
San Mateo 25
Bengaluru 24
Columbus 24
Brussels 23
Phoenix 22
Denver 21
Shenyang 21
Redondo Beach 20
Rio de Janeiro 20
Council Bluffs 19
Düsseldorf 19
Lancaster 19
Rome 19
Chicago 16
Florence 16
Jiaxing 16
Kunming 16
Nanchang 16
Tokyo 16
Warsaw 16
Brooklyn 15
Changsha 15
Hebei 15
Johannesburg 15
San Diego 15
Tianjin 14
Jinan 13
Milan 13
Atlanta 11
Chennai 11
Mexico City 11
San Francisco 11
Belo Horizonte 10
Brno 10
Menlo Park 10
Málaga 10
Portsmouth 10
Guangzhou 9
Toronto 9
Baghdad 8
Falls Church 8
Frankfurt am Main 8
Goiânia 8
Manchester 8
Naples 8
Stockholm 8
Washington 8
Abidjan 7
Berlin 7
Boston 7
Brasília 7
Izmir 7
Nairobi 7
Olomouc 7
Orem 7
Poplar 7
Uberlândia 7
Ankara 6
Guarulhos 6
Lauterbourg 6
Mestre 6
Totale 11.274
Nome #
Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry) 994
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 739
The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines 404
B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function. 347
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study 335
Sex-related differences in chronic heart failure 324
Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. 310
B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function 309
Myocardial 123I-metaiodobenzylguanidine imaging in hypertension and left ventricular hypertrophy 282
H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease 279
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure 272
Natriuretic peptides in heart failure: where we are, where we are going. 271
Different diuretic dose and response in acute decompensated heart failure: Clinical characteristics and prognostic significance 265
Quantitative evaluation of microvessels in Behcet's disease 261
Cross-sectional study: CagA-positive Helicobacter pylori infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide 253
Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. 249
Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia 247
Prognostic significance of hyperuricemia in patients with acute heart failure 242
Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure 238
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 237
Comparison of neutrophil gelatinase-associated lipocalin versus B-type natriuretic peptide and cystatin C to predict early acute kidney injury and outcome in patients with acute heart failure 236
Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model 234
Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial 227
The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions 218
Clinical impact of BNP and other emerging biomarkers in heart failure evaluation and management 214
Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy 213
Patients with cardiorenal syndrome revealed increased neurohormonal activity, tubular and myocardial damage compared to heart failure patients with preserved renal function 211
The role of fibrosis and inflammation for response and outcome prediction in candidates to cardiac resynchronization therapy: is response the right answer? 207
Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application 207
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure 198
Definizione di pattern videocapillaroscopici (VCS) di normalità nel microcircolo cutaneo. Stratificazione secondo l'età 192
The role of natriuretic peptides for the diagnosis of left ventricular dysfunction 191
Natriuretic peptides and NGAL in heart failure: does a link exist? 189
Diagnostic utility of contemporary echo and BNP assessment in patients with acute heart failure during early hospitalization 187
Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection 183
Current therapeutic strategies in cardiorenal syndrome 179
Heart failure: pathophysiology and clinical picture. 178
The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study 174
Dyslipidemias and fibrinolysis. 173
Left ventricular hypertrophy differences in male professional runners and in young patients suffering from mild hypertension 169
Peptide natriuretico di tipo B ed ecocardiografia Doppler nella diagnosi di scompenso cardiaco: Metodiche alternative o complementari? [B-type natriuretic peptide and Doppler echocardiography in the diagnosis of heart failure: alternative or complementary tools?] 167
The potential role of natriuretic peptides in acute coronary syndrome stratification 158
Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact? 148
A multidisciplinary approach in neurofibromatosis 1 145
Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients 141
From gene mutations to biomechanical abnormalities and electrophysiological remodeling in hypertrophic cardiomyopathy: exploring the translational approach. 141
Arterial hypertension and atrial fibrillation: Standard and advanced echocardiography from diagnosis to prognostication 137
Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries 134
Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure 129
Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction 128
null 122
Pulmonary congestion assessment in heart failure: traditional and new tools 120
null 120
Combined BNP and Echocardiographic assessment in interstitial lung disease for pulmonary hypertension detection 119
Clinical impact of oral antidiabetic medications in heart failure patients 119
null 111
null 105
Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes 100
null 100
The prognostic combined role of B-type natriuretic peptide, blood urea nitrogen and congestion signs persistence in patients with acute heart failure 97
Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF 94
Additional value of Galectin-3 respect to BNP in acute heart failure patients with preserved ejection fraction 89
Infection by CagA-positive Helicobacter pylori strains in patients with ischemic heart disease: prevalence and association with exercise-induced electrocardiographic abnormalities. 87
Usefulness of combined ultrasound assessment of E/e' ratio, pulmonary pressure, and cava vein status in patients with acute heart failure 85
Effects of metolazone administration on congestion, diuretic response and renal function in patients with advanced heart failure 83
Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care 81
Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure 79
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population (Vascular Health and Risk Management (2008) 4, 4 (877-883)) 78
Cardio-renal syndrome revealed increased neurohormonal activity, tubular and myocardial damage respect to heart failure patients with preserved renal function 77
Clinical impact of renal dysfunction in heart failure 76
The role of fibrosis, inflammation, and congestion biomarkers for outcome prediction in candidates to cardiac resynchronization therapy: is “response” the right answer? 76
The predictive value of plasma biomarkers in discharged heart failure patients: the role of plasma BNP 71
Chronotropic incompetence across heart failure categories 68
Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF 66
Right ventricular dysfunction in chronic heart failure: Clinical laboratory and echocardiographic characteristics. (the RIVED-CHF registry) 62
Heart failure outpatient clinics resources in Italy: a viewpoint of Italian Society of Cardiology organization 60
Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature 60
The relevance of specific heart failure outpatient programs in the COVID era: An appropriate model for every disease 59
Continuous versus intermittent loop diuretics infusion dosing in acute heart failure: effects on renal function, outcome and BNP levels 57
Integrated Cardiorespiratory Rehabilitation and Its Impact on Cardio-Renal-Metabolic Profile After Cardiac Surgery 57
Patient phenotype profiling using echocardiography and natriuretic peptides to personalise heart failure therapy 53
Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update 52
Contemporary assessment of lung ultrasound, BNP and echocardiography for outcome prediction in patients with decompensated heart failure 51
Different neurohormonal and inflammatory pattern in acute CRS respect to AHF patients with preserved renal function 51
Contemporary assessment of lung ultrasound, bnp and echocardiography predicts outcome in patients with acute heart failure independently to systolic dysfunction 46
Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction 45
Resistant hypertension: An overview 42
The assessment, interpretation and implementation of lung ultrasound examinations in Heart Failure: Current evidence and gaps in knowledge 42
The importance of integrated left atrial evaluation: From hypertension to heart failure with preserved ejection fraction 37
Combination Between Biomarkers and Echocardiographic Data for Prediction of Left Ventricular Reverse Remodelling in Cardiac Resynchronization Therapy 35
The Role of Lung Ultrasound Scan in Different Heart Failure Scenarios: Current Applications and Lacks of Evidences 32
Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence 31
Multi-biomarkers laboratory strategy for outcome prediction in patients with severe systolic dysfunction submitted to CRT 31
Dynamic variation of renal function and novel or old HF biomarkers (ST2, Galectin 3, NT-proBNP) and response to cardiac resynchronization therapy (CRT) 26
Transient versus persistent worsening renal function during hospitalization in acute heart failure: different phenotypes for different outcome 24
Plasma Neuthrophil Gelatinase associated Lipocalin (NGAL) predict worsening renal function and outcome in patients with acute decompensated heart failure 22
Incidental cardiac mass: Differential diagnosis, clinical approach and review of the literature,Massa cardiaca incidentale: Diagnosi differenziale, approccio clinico e revisione della letteratura 7
Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated 5
Totale 15.476
Categoria #
all - tutte 39.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.784


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021695 0 0 0 0 0 92 41 154 63 98 77 170
2021/2022648 34 70 31 70 60 24 28 24 38 72 65 132
2022/20231.019 61 90 136 131 112 189 24 80 87 20 32 57
2023/2024889 46 22 96 44 19 228 309 21 5 24 12 63
2024/20252.169 41 71 140 107 236 168 113 105 172 101 275 640
2025/20266.586 488 1.669 2.230 905 1.251 43 0 0 0 0 0 0
Totale 15.476